Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale)
Conditions
Brief summary
To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.
Interventions
2g per day
DRUGplacebo
twice per day
Sponsors
University of Catania
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Inclusion criteria
* patients with severe hepatic encephalopathy (grade 3 of the West Haven grading scale) with hepatic cirrhosis
Exclusion criteria
* Patients with a history of recent alcohol abuse, patients using psychotropic drugs (e.g., antipsychotics, interferon, benzodiazepines, anti-epileptics, sedatives and antidepressants) * Other
Countries
Italy
Outcome results
None listed